Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1134

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1134
---
 continuing negative publicity could continue to have a negative impact on our operating results.

Risks Related to Our Limited Operating History

Lunai Bioworks is a pre-clinical
biotechnology company and may never be able to successfully develop marketable products or generate any revenue. We have a very limited
relevant operating history upon which an evaluation of our performance and prospects can be made. There is no assurance that our future
operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease operations.

Lunai Bioworks is an early-stage
biotechnology company and has not generated any revenues to date. All of our product candidates are in the discovery stage or pre-clinical
development stage. Moreover, we cannot be certain that our research and development efforts will be successful or, if successful, that
our potential treatments will ever be approved for sale to generate commercial revenues. Our therapeutic pipeline includes cell, gene
and immunotherapy involving genetically modified cells targeted to treat cancer, and we rely on third parties under contract in the development
of product candidates in our pipeline. There is no guarantee that we will be able to manage and fund the development of a pipeline with
multiple target conditions, nor that third parties will meet their obligations to us in connection with our research and development.
We and certain third parties, on which we rely, have no relevant operating history upon which an evaluation of our performance and prospects
can be made. We are subject to all of the business risks associated with a new enterprise, including, but not limited to, risks of unforeseen
capital requirements, failure of treatments either in non-clinical testing or in clinical trials, failure to establish business relationships,
failure of our third parties to meet their obligations to us and competitive disadvantages against larger and more established companies.
If we fail to become profitable, we may suspend or cease operations.

Renovaro
Cube and BioSymetrics are artificial intelligence (“AI”)-driven healthcare technology companies operating in a rapidly evolving
field with a limited operating history, which makes it difficult to evaluate their current business and predict Renovaro Cube’s
future performance.

Renovaro
Cube and BioSymetrics are AI-driven healthcare technology companies operating in a rapidly evolving field and, having commenced operations
in 2013 and 2017, respectively, have a limited operating history. Renovaro Cube shifted its business from the financial technology
(or FinTech) industry to cancer diagnostics in 2018 and does not have a commercial product for sale